ASLAN Pharmaceuticals (ASLN) Scheduled to Post Quarterly Earnings on Friday

ASLAN Pharmaceuticals (NASDAQ:ASLN) is set to release its earnings data on Friday, April 26th.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last announced its quarterly earnings data on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. On average, analysts expect ASLAN Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ASLAN Pharmaceuticals Price Performance

Shares of ASLN opened at $0.47 on Thursday. The business’s fifty day moving average price is $0.61 and its 200 day moving average price is $0.72. ASLAN Pharmaceuticals has a 12-month low of $0.39 and a 12-month high of $4.69. The stock has a market capitalization of $7.68 million, a PE ratio of -0.17 and a beta of 1.45.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ASLN. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of ASLAN Pharmaceuticals in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $10.00 target price (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.